vtama news - Search News

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.

Seeking Alpha · 15h

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.

NJBIZ · 22h

Organon to acquire Dermavant in $1.2B deal

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

MarketWatch · 1d

Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million,

MT Newswires on MSN · 1d

Organon to Buy Roivant's Dermatology Unit For Up to $1.2 Billion

Organon (OGN) on Wednesday agreed to acquire Roivant Sciences' (ROIV) immuno-dermatology subsidiary, Dermavant, in a deal worth up to $1.2 billion. The healthcare company will pay $175 million upfront and up to $950 million for the achievement of certain commercial milestones.

Pharmabiz4h

Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

FiercePharma2d

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama

Organon will also furnish Dermavant with a $75 million milestone payment contingent upon Vtama’s approval in atopic ...

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

Armed robbery in Revesby2d

Organon Acquires Dermavant and VTAMA Therapy

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...

Finanznachrichten1d

Roivant Sciences: Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed ...

1don MSN

Roivant Flips a Skin Drug to Organon

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...

Investing1mon

Roivant Sciences stock held at 'Buy' by H.C. Wainwright despite slower Vtama launch

The analyst pointed out that the launch of Vtama for psoriasis has experienced a slowdown. Despite this, the firm remains optimistic about the drug's potential in the atopic dermatitis market ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics